Urothelial Cancer Treatment Market to Reach $14.8 Billion by 2035

Urothelial cancer treatment market was valued at $5.1 billion in 2025 and is projected to reach $14.8 billion by 2035, growing at a CAGR of 11.3% during the forecast period (2026–2035). The increasing global burden of cancer, alongside rising adoption of advanced oncology therapies, is significantly driving demand for urothelial cancer treatments. Governments and healthcare systems are strengthening cancer control programs, improving early diagnosis rates, and expanding access to innovative therapies, thereby accelerating market growth. The shift toward precision medicine and immunotherapy is further transforming treatment paradigms, improving patient survival outcomes, and fueling investment across pharmaceutical pipelines.

Browse the full report description of “Urothelial Cancer Treatment Market Size, Share & Trends Analysis Report, By Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy, Surgery), By Drug Class (Immune Checkpoint Inhibitors, Cytotoxic Agents, Kinase Inhibitors, Monoclonal Antibodies, Combination Therapies), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/urothelial-cancer-treatment-market

Immunotherapy and targeted therapy are gaining significant traction due to their improved efficacy and reduced toxicity compared to conventional chemotherapy. While chemotherapy continues to hold a substantial share, the adoption of immune checkpoint inhibitors and combination therapies is expanding rapidly across both developed and emerging healthcare markets. Increasing awareness, favourable reimbursement frameworks, and ongoing clinical advancements are further supporting the long-term growth of the urothelial cancer treatment market.

Rising Global Cancer Burden and Government Initiatives Driving Market Expansion

The growing incidence of cancer is a key macro driver supporting the expansion of the urothelial cancer treatment market. According to the World Health Organization (WHO), global cancer cases reached approximately 20 million new cases in 2022, with projections indicating a rise to over 35 million cases by 2050. Additionally, data from the U.S. National Cancer Institute (NCI) highlights that bladder cancer, a major form of urothelial cancer, accounted for an estimated 83,000 new cases in the United States in 2024, emphasizing the increasing disease burden.

Government-led initiatives are playing a critical role in strengthening oncology care infrastructure. For instance, in 2023, the U.S. government expanded funding under the Cancer Moonshot initiative to accelerate immunotherapy research and targeted cancer treatments. Similarly, the European Commission’s Europe’s Beating Cancer Plan (ongoing through 2025) continues to support early detection, research funding, and equitable access to innovative therapies across member states. These initiatives are directly contributing to increased adoption of advanced treatment modalities, including immune checkpoint inhibitors and monoclonal antibodies, thereby boosting market demand.

In addition, regulatory approvals and accelerated pathways for oncology drugs between 2023 and 2025 have enhanced market accessibility. Agencies such as the U.S. Food and Drug Administration (FDA) have continued to approve novel immunotherapies and combination regimens for urothelial cancer, improving treatment outcomes and expanding therapeutic options. These developments are reinforcing strong growth momentum across the urothelial cancer treatment market globally.

Innovation Leaders Transforming the Urothelial Cancer Treatment Market

The key players in the urothelial cancer treatment market include Merck & Co., Pfizer Inc., Astellas Pharma, Roche (Genentech), and Bristol Myers Squibb, among others. These companies are actively investing in research and development to advance immuno-oncology therapies, targeted drugs, and combination treatment strategies aimed at improving clinical outcomes and extending patient survival.

• In November 2025, the S. Food and Drug Administration approved pembrolizumab in combination with Enfortumab vedotin-EJFV for muscle-invasive bladder cancer, marking a significant advancement in the urothelial cancer treatment market. Developed by Merck & Co. in collaboration with Astellas Pharma, the regimen demonstrated substantial improvements in event-free and overall survival compared to surgery alone.

• In May 2024, Bristol Myers Squibb strengthened its position in the urothelial cancer treatment market with the European Commission approval of Opdivo in combination with chemotherapy (cisplatin and gemcitabine) for first-line treatment of unresectable or metastatic urothelial carcinoma. This marks the first approved concurrent immunotherapy-chemotherapy regimen in the EU for this indication, demonstrating significant improvements in overall and progression-free survival in the CheckMate-901 trial.

Market Coverage

• The market number available for – 2025–2035
• Base year – 2025
• Forecast period – 2026–2035
• Segment Covered –
• By Treatment Type
• By Drug Class
• Competitive Landscape – Merck & Co., Pfizer Inc., Astellas Pharma, Roche (Genentech), and Bristol Myers Squibb, among others.

Key Questions Addressed by the Report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Urothelial Cancer Treatment Market Segment

By Treatment Type

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy
• Surgery

By Drug Class

• Immune Checkpoint Inhibitors
• Cytotoxic Agents
• Kinase Inhibitors
• Monoclonal Antibodies
• Combination Therapies

Global Urothelial Cancer Treatment Market Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/urothelial-cancer-treatment-market